Australia approves cannabis exports as the ‘Golden State’ goes green
Published 05-JAN-2018 09:00 A.M.
6 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
As of the first of January, California became the largest state in the US to legalise recreational cannabis use.
This much-anticipated piece of news comes two decades after the state became the first to legalise marijuana for medicinal use. It goes back to California’s successful 2016 ballot initiative which saw 57 per cent of voters electing to fully legalise marijuana.
Under the new law, which kicked in on New Year’s Day, adults aged 21 or older no longer need a medical license to buy and use the drug, and can use, carry and buy up to an ounce of marijuana for non-medical use, as well as grow up to six plants at home.
On domestic shores, the Australian government announced yesterday it would be allowing the export of certain cannabis products to international markets — a move which needs to pass Federal parliament when it returns to sessions in February 2018.
As could be expected, ASX-listed small-cap Creso Pharma Limited (ASX:CPH) has enthusiastically welcomed the news from the government. CEO Dr Miri Halperin Wernli stated, “This move by the Australian Government not only confirms what we have been doing for the past 18 months, but it’s a major step forward to fast track the ability to get medicinal cannabis into the hands of patients who need it. This will place Australia in a unique role as other nations scramble to find safe and legal supplies of medicinal cannabis.”
It should be noted that CPH is an early stage company and investors should seek professional financial advice if considering this stock for their portfolio.
Minister for Health, Greg Hunt, stated that the government hopes the legislative change will pave the way for Australia to become the world’s number one medicinal cannabis supplier.
California’s New Year’s Day sales
According to Californian state estimates, more than 400 state-licensed cannabis businesses were operating on New Year’s Day across California. Dispensaries in San Diego, Santa Cruz, the Palm Springs Area and the San Francisco Bay Area conducted the majority of Californian recreational cannabis sales, as prospective retailers needed to have both city and state licenses to participate in the first day of sales.
The sale of cannabis in California is still subject to strict conditions — it must be bought from a licensed dispensary, with proof of legal age required for purchase.
Legal buyers in the newly created market will also now have to pay state, sales and municipal taxes, which will generate an estimated US$1 billion per year. Technically, the US federal government still classifies the drug as a controlled substance, alongside heroin and cocaine.
That did not stop Californians on New Year’s Eve, however, as some raised marijuana joints in lieu of more traditional champagne to toast the turn of midnight.
To date, 29 US states have adopted medical marijuana laws. Alongside California, seven other states, as well as the District of Columbia, have legalised recreational pot, comprising a budding market that investment bank Cowen and Co. (Nasdaq:COWN) predicts will grow to US$50 billion by 2026.
Cowen researchers estimate that legalisation in California alone will triple the size of the nation’s legal cannabis industry within a decade. According to research firm BDS Analytics, the market for marijuana in California specifically — the world’s sixth largest economy with a population nearing 40 million — is expected to reach US$3.7 billion this year and more than US$5.1 billion in 2019.
“This is an historic day for the state of California,” Bureau of Cannabis Control Chief Lori Ajax told Green State on New Year’s Day.
“It marks the beginning of a legal cannabis marketplace that will be well regulated in order to protect consumers and maintain a level playing field for cannabis-related businesses. We are hopeful that we have put forth a model that other states will look to as an example when they head down the path to legalization.”
Green State writer David Downs noted: “Most folks who want or need cannabis already know how to get it in California, which has had medical marijuana for 21 years. But Jan. 1, 2018 signifies a milestone — similar to the end of alcohol prohibition Dec. 5, 1933.”
What about tax and regulatory systems?
Some commentators have pointed out that in light of the complex web of taxes and regulations created to govern sales of the drug, the ensuing red tape will make things patchy to begin with.
As cities determine their own regulation, and supply and demand is established, “the first year, two years are going to be a mess,” Troy Dayton told AFP news agency. Dayton is CEO of Arcview, a company that analyses the global cannabis market. He said that there could be “crazy fluctuation in price over the first year or two.”
California news sees spike in pot stocks
Hot on the heels of this development, US and Canadian pot stocks are spiking. And the ASX’s collection of pot stocks, which as a whole saw some considerable highs in 2018, seems to be moving in a similar direction.
Take, for example, the aforementioned Creso Pharma (ASX:CPH), as well as MGC Pharmaceuticals (ASX:MXC) and the Hydroponics Company (ASX:THC). While these ASX stocks don’t necessarily have direct exposure to the US pot market, this may well be a sign of things to come — a green light, so to speak.
That said, all three companies are at early stages and represent a speculative investment. As such investors should seek professional financial advice if considering this stock for their portfolio.
Domestically, the main debate about marijuana has centred on its medicinal use. Last year, the Australian federal government loosened restrictions around cannabis importation to treat a range of medical illnesses from epilepsy to cancer, representing a legislative landmark that sparked a surge in ASX pot stocks.
Regulations that currently prevent exports of medicinal cannabis products will be changed once parliament resumes in February. The legislative changes around exports will cover cannabis-based treatments such as oils, patches, sprays, lozenges and tablets that have the potential to relieve the pain and symptoms of a diverse range of conditions.
This is a move that’s both practical and strategic, aiming to cultivate a wider market for locally produced medicine to provide a more stable supply for Australian patients, and also setting up ambitions for Australian to emerge as a leading global producer of medicinal marijuana products. But is Australia receptive to legalising recreational usage? Cannabis advocate Greg Barns told 9 News that it’s inevitable.
“There is a global trend now, not just in California, but you will see on July 1 this year, the whole of Canada moving to legalise the personal use of cannabis,” said Barns.
This article is General Information and contains only some information about some elements of one or more financial products. It may contain; (1) broker projections and price targets that are only estimates and may not be met, (2) historical data in terms of earnings performance and/or share trading patterns that should not be used as the basis for an investment as they may or may not be replicated. Those considering engaging with any financial product mentioned in this article should always seek independent financial advice from a licensed financial advisor before making any financial decisions.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.